Corgenix Receives Third United States Patent on AtherOx Technology.Corgenix Medical Corporation (Denver, CO), a worldwide developer and marketer of diagnostic test kits, has received notification of United States Patent and Trademark Office The United States Patent and Trademark Office (PTO or USPTO) is an agency in the United States Department of Commerce that provides patent protection to inventors and businesses for their inventions, and trademark registration for product and intellectual property approval for technology to which Corgenix holds exclusive worldwide licensing rights outside of Japan. The technology is incorporated in the company's AtherOx product group, a next-generation technology to identify individuals at risk for developing atherosclerotic cardiovascular disease. United States Patent 7,422,864, entitled Method for Measuring Oxidized oxidized having been modified by the process of oxidation. oxidized cellulose see absorbable cellulose. LDL-CRP Complex and Measurement Kit, describes the binding of oxidized low-density lipoprotein (oxLDL) with C-reactive protein (CRP C-reactive protein (CRP) A protein present in blood serum in various abnormal states, like inflammation. Mentioned in: Pelvic Inflammatory Disease CRP, n.pr See C-reactive protein. ) resulting in oxLDL/CRP (CRP-AtherOx) complex formation, and the immunoassay Immunoassay An assay that quantifies antigen or antibody by immunochemical means. The antigen can be a relatively simple substance such as a drug, or a complex one such as a protein or a virus. method for measuring these complexes in blood. CRP is an inflammatory protein that has been associated with risk of cardiovascular disease. High levels of CRP can be found in many inflammatory and infectious disorders, but oxLDL/CRP complexes were more specific and predictive of atherosclerotic cardiovascular disease (Tabuchi et al. J Lipid Res 2007; 48:768-781). The latest patent adds to previous United States patents (5,900,359 issued May 4, 1999, Method for Determination of Oxidized Lipoproteins Lipoproteins The packages in which cholesterol and triglycerides travel throughout the body. Mentioned in: Lipoproteins Test lipoproteins (lip´ōprō´tēns), n. and Use Thereof, and 7,160,733 issued January 9, 2007, Ligand Specific to B2-glycoprotein I and Use Thereof. These patents described the specific interaction of B2-glycoprotein I with the oxidized form of low-density lipoprotein (oxLDL) leading to the formation of oxLDL/B2-glycoprotein I complexes (AtherOx). This interaction does not occur with the native or non-oxidized form of LDL LDL - ["LDL: A Logic-Based Data-Language", S. Tsur et al, Proc VLDB 1986, Kyoto Japan, Aug 1986, pp.33-41]. . An immunoassay for the detection of the complexes was described which provides the basis for the AtherOx test kits. Douglass Simpson, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Corgenix said, "We are very pleased to announce this important addition to our IP portfolio. We have one product already cleared by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and several products in the later stages of the development pipeline with FDA submission expected in the next year or so. Since cardiovascular disease is one of the world's leading causes of death, the early detection of atherosclerosis has become increasingly important, and we are optimistic about our ability to serve this significant market." In all countries where the use of products employing this technology have not been cleared, the products shall not be used for diagnostic use as the performance characteristics have not been established. The AtherOx technology utilizes oxidized low-density-lipoprotein (oxLDL) complexed with the plasma protein B2GPI (Graphical Programming Interface) A graphics language in OS/2 Presentation Manager. It is a derivative of the GDDM mainframe interface and includes Bezier curves. . Although oxLDL has been implicated in cardiovascular disease, according to results published in the Annals of N.Y. Academy of Science (2007), determination of oxLDL/.2GPI complexes, rather than oxLDL alone, may be a more physiologic and accurate way of assessing the risk of progressive atherosclerotic cardiovascular disease in individuals with systemic lupus erythematosus Systemic Lupus Erythematosus Definition Systemic lupus erythematosus (also called lupus or SLE) is a disease where a person's immune system attacks and injures the body's own organs and tissues. Almost every system of the body can be affected by SLE. and lupus-like disorders. Corgenix licensed this technology in 2002, and is developing additional products utilizing this unique platform. In addition to the three United States patents which have been issued, several others are pending. Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for vascular diseases, immunology disorders, and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 52 diagnostic products through a global distribution network. Corgenix Medical Corporation +1-303-453-8903 www.corgenix.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion